BMJ  2007;335:1057-1058 (24 November), doi:10.1136/bmj.39365.511076.BE

Editorials

Rate control in permanent atrial fibrillation

Guidelines on the use of digoxin are inconsistent with evidence from randomised trials

Atrial fibrillation is the most common cardiac arrhythmia and it causes substantial morbidity, especially in elderly people. In June 2006, the UK National Institute for Health and Clinical Excellence (NICE) published new guidelines for control of heart rate in people with chronic atrial fibrillation.1 The guidelines depart from historical practice by recommending that instead of digoxin, β adrenoceptor blockers or rate limiting calcium antagonists should be the preferred initial monotherapy, except in predominantly sedentary people. Similarly, the revised 2006 joint American College of Cardiology/American Heart Association/European Society of Cardiology (ACC/AHA/ESC) guidelines recommend the use of β blockers or calcium antagonists alone to control heart rate.2 We have reviewed the evidence to support this fundamental change in practice and challenge its safety.

No single definition of ideal control of heart rate in chronic atrial fibrillation exists.3 Rate control drugs aim to reduce heart rate at rest and during exercise, without causing excessive nocturnal bradycardia. The ultimate aim of treatment is to improve symptoms and exercise tolerance, and to prevent cardiomyopathy induced by tachycardia. To reduce morbidity, the benefits of treatment need to be weighed against the harms. A substudy of the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study found no association between achieved ventricular rate and overall survival or quality of life.4

Epidemiological studies in the United Kingdom and the United States have reported an overall decline in the use of digoxin, perhaps as a result of recent recommendations. People with atrial fibrillation sometimes take β blockers or calcium antagonists for indications other than arrhythmia. In a descriptive study of the management of rate control in 2027 people, the AFFIRM investigators reported no significant difference in adequate control of heart rate at rest and exercise in people treated with β blockers alone or digoxin alone, which suggests that digoxin is still one of the first line drugs for the management of heart rate.5

Of previously published systematic reviews,6 7 one highlighted the lack of evidence on optimal control of heart rate in people with atrial fibrillation and the importance of symptom control. In the other, the comparisons of β blockers and calcium antagonists with placebo were confounded by most patients on either treatment arm also being on digoxin.6 Clearly, larger randomised trials are needed to inform prescribing decisions. However, the current evidence on which recommendations have been made is summarised below.

We searched the literature using the Medline, PubMed, and Cochrane databases for studies published in English. By reviewing bibliographies of relevant articles we identified additional studies. We reviewed 57 studies, including 25 randomised double blind controlled trials, assessing digoxin, β blockers, calcium antagonists, and combinations for rate control in chronic atrial fibrillation. The smallest trial recruited six participants and the largest included 136. Differences in methodology and outcomes make direct comparisons difficult. Only a minority of studies reported symptom scores and patient preferences.

Digoxin has long been used for control of heart rate in chronic atrial fibrillation. It acts primarily by exerting a vagomimetic influence on the atrioventricular node and has a positive inotropic effect. It has few side effects but has a flat dose-response curve and a narrow therapeutic index, so that subtherapeutic doses are often used. It is less effective at controlling heart rate during exercise and in states of increased sympathetic activation.

In people with atrial fibrillation, β adrenoceptor blockers have heterogeneous effects on heart rate, depending on their specificity for the β receptor and how much concomitant β agonist activity they possess. Ten studies8 9 10 11 12 13 14 15 16 17 evaluated β blockers alone. The β blocker was better than digoxin in controlling heart rate at rest in only one study,8 although it improved heart rate during exercise in four studies.8 9 11 15 Xamoterol (discontinued in the United Kingdom in 2000) was the only β blocker to improve exercise tolerance compared with digoxin, but at the expense of worsening control of heart rate.13 In six other studies, exercise capacity did not improve when β blockers were used alone. In comparison, several studies have shown that better heart rate control at rest and during exercise is achieved with combined digoxin and a β blocker than with digoxin alone.8 14 18 19 20 21 22 23 24 25 26 27 28 However, the effect of this combination on exercise tolerance is not consistent—some studies reported deterioration in exercise capacity,18 19 21 23 28 some reported improvement,13 22 24 and others reported no change.14 15 18 20 25 27 29 Other side effects were reported with the use of β blockers in the above studies and, importantly, two studies reported worsening symptoms of heart failure on withdrawal of digoxin in people with heart failure.13 14

The calcium channel blocker diltiazem has been evaluated in five studies.15 30 31 32 33 They found that diltiazem was better than digoxin at controlling heart rate during exercise, but not during rest, and no improvement was seen in exercise capacity. Eleven studies15 21 22 30 32 33 34 35 36 37 38 assessed the combination of diltiazem and digoxin; most of these reported improved heart rate control at rest and exercise when compared with digoxin alone. Two also found improved exercise tolerance with the combination.22 36 One person developed worsening heart failure after discontinuation of digoxin while receiving diltiazem 360 mg daily.33 In another study, two people with previous episodes of heart failure deteriorated when digoxin was discontinued.30

Results were similar when monotherapy with verapamil was compared with digoxin. Verapamil improved heart rate during exercise compared with digoxin in three studies.31 39 40 Exercise tolerance with verapamil alone improved in two of the three studies that tested it.17 40 The combination of digoxin with verapamil provided better heart rate control at rest and during exercise than digoxin alone.20 18 36 41 42 43 44 45 46 However, bradycardic episodes or pauses were sometimes seen with the combination. Exercise tolerance was not consistently improved despite better heart rate control, with some studies reporting improvement36 40 41 and others no change.18 20 44 47 Concomitant use of both drugs increases digoxin concentrations.

Limitations to the use of verapamil and diltiazem include their negative inotropic effects and considerable dose related side effects.

In patients with chronic atrial fibrillation, digoxin has been the mainstay of treatment for many years, so new recommendations relegating digoxin should be evidence based and safe. We believe that little evidence exists that monotherapy with β blockers or calcium channel blockers improves exercise tolerance compared with digoxin. On the contrary, there is clear evidence that when β blockers are used alone, exercise capacity may worsen, especially in people with a history of heart failure.

Similarly, little evidence exists that monotherapy with these drugs improves heart rate control at rest and during exercise compared with digoxin alone. Beneficial effects on heart rate variability, together with improved exercise tolerance, have only been shown with the combination of digoxin and a β blocker or calcium channel blocker. We believe that the combination of digoxin and a β blocker or calcium antagonist should be recommended as first line management. We would emphasise that it is safest to start treatment with digoxin first.

 

 

Theodora Nikolaidou, research fellow, Kevin S Channer, consultant cardiologist and physician

Royal Hallamshire Hospital, Sheffield S10 2JF

nikolaidou{at}btinternet.com

Competing interests: None declared.

Provenance and peer review: Not commissioned; externally peer reviewed.

References

  1. National Collaboration Centre for Chronic Conditions. Atrial fibrillation: national clinical guideline for management in primary and secondary care. London: Royal College of Physicians, 2006.
  2. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation—executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). J Am Coll Cardiol 2006;48:854-906.[Free Full Text]
  3. Channer KS. The drug treatment of atrial fibrillation. Br J Clin Pharmacol 1991;32:267-73.[ISI][Medline]
  4. Cooper HA, Bloomfield DA, Bush DE, Katcher MS, Rawlins M, Sacco JD, et al. Relation between achieved heart rate and outcomes in patients with atrial fibrillation (from the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study). Am J Cardiol 2004;93:1247-53.[CrossRef][ISI][Medline]
  5. Olshansky B, Rosenfeld LE, Warner AL, Solomon AJ, O'Neill G, Sharma A, et al. The atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol 2004;43:1201-8.[Abstract/Free Full Text]
  6. Segal JB, McNamara RL, Miller MR, Kim N, Goodman SN, Powe NR, et al. The evidence regarding the drugs used for ventricular rate control. J Fam Pract 2000;49:47-59.[ISI][Medline]
  7. Bjerregaard P, Bailey WB, Robinson SE. Rate control in patients with chronic atrial fibrillation. Am J Cardiol 2004;93:329-32.[CrossRef][ISI][Medline]
  8. David D, Segni ED, Klein HO, Kaplinsky E. Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: beneficial effect of an added beta adrenergic blocking agent. Am J Cardiol 1979;44:1378-82.[CrossRef][ISI][Medline]
  9. Ang EL, Chan WL, Cleland JG, Moore D, Krikler SJ, Alexander ND, et al. Placebo controlled trial of xamoterol versus digoxin in chronic atrial fibrillation. Br Heart J 1990;64:256-60.[Abstract/Free Full Text]
  10. Matsuda M, Matsuda Y, Yamagishi T, Takahashi T, Haraguchi M, Tada T, et al. Effects of digoxin, propranolol, and verapamil on exercise in patients with chronic isolated atrial fibrillation. Cardiovasc Res 1991;25:453-7.[ISI][Medline]
  11. Wong CK, Lau CP, Leung WH, Cheng CH. Usefulness of labetalol in chronic atrial fibrillation. Am J Cardiol 1990;66:1212-5.[CrossRef][ISI][Medline]
  12. Wang R, Camm J, Ward D, Washington H, Martin A. Treatment of chronic atrial fibrillation in the elderly, assessed by ambulatory electrocardiographic monitoring. J Am Geriatr Soc 1980;28:529-34.[ISI][Medline]
  13. Lawson-Matthew PJ, McLean KA, Dent M, Austin CA, Channer KS. Xamoterol improves the control of chronic atrial fibrillation in elderly patients. Age Ageing 1995;24:321-5.[Abstract/Free Full Text]
  14. Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JG. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol 2003;42:1944-51.[Abstract/Free Full Text]
  15. Farshi R, Kistner D, Sarma JS, Longmate JA, Singh BN. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol 1999;33:304-10.[Abstract/Free Full Text]
  16. Hsieh MH, Chen SA, Wen ZC, Tai CT, Chiang CE, Ding YA, et al. Effects of antiarrhythmic drugs on variability of ventricular rate and exercise performance in chronic atrial fibrillation complicated with ventricular arrhythmias. Int J Cardiol 1998;64:37-45.[CrossRef][ISI][Medline]
  17. Tsuneda T, Yamashita T, Fukunami M, Kumagai K, Niwano S, Okumura K, et al. Rate control and quality of life in patients with permanent atrial fibrillation: the quality of life and atrial fibrillation (QOLAF) study. Circ J 2006;70:965-70.[CrossRef][ISI][Medline]
  18. Lewis RV, McMurray J, McDevitt DG. Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation. J Cardiovasc Pharmacol 1989;13:1-6.[ISI][Medline]
  19. DiBianco R, Morganroth J, Freitag JA, Ronan JA Jr, Lindgren KM, Donohue DJ, et al. Effects of nadolol on the spontaneous and exercise-provoked heart rate of patients with chronic atrial fibrillation receiving stable dosages of digoxin. Am Heart J 1984;108:1121-7.[CrossRef][ISI][Medline]
  20. Lundstrom T, Moor E, Ryden L. Differential effects of xamoterol and verapamil on ventricular rate regulation in patients with chronic atrial fibrillation. Am Heart J 1992;124:917-23.[CrossRef][ISI][Medline]
  21. Myers J, Atwood JE, Sullivan M, Forbes S, Friis R, Pewen W, et al. Perceived exertion and gas exchange after calcium and beta-blockade in atrial fibrillation. J Appl Physiol 1987;63:97-104.[Abstract/Free Full Text]
  22. Koh KK, Song JH, Kwon KS, Park HB, Baik SH, Park YS, et al. Comparative study of efficacy and safety of low-dose diltiazem or betaxolol in combination with digoxin to control ventricular rate in chronic atrial fibrillation: randomized crossover study. Int J Cardiol 1995;52:167-74.[CrossRef][ISI][Medline]
  23. Atwood JE, Sullivan M, Forbes S, Myers J, Pewen W, Olson HG, et al. Effect of beta-adrenergic blockade on exercise performance in patients with chronic atrial fibrillation. J Am Coll Cardiol 1987;10:314-20.[Medline]
  24. Molajo AO, Coupe MO, Bennett DH. Effect of Corwin (ICI 118587) on resting and exercise heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation. Br Heart J 1984;52:392-5.[Abstract/Free Full Text]
  25. Brodsky M, Saini R, Bellinger R, Zoble R, Weiss R, Powers L. Comparative effects of the combination of digoxin and dl-sotalol therapy versus digoxin monotherapy for control of ventricular response in chronic atrial fibrillation. dl-Sotalol Atrial Fibrillation Study Group. Am Heart J 1994;127:572-7.[CrossRef][ISI][Medline]
  26. Cristodorescu R, Rosu D, Deutsch G, Verdes A, Luca C. The heart rate slowing effect of pindolol in patients with digitalis resistant atrial fibrillation and heart failure. Med Interne 1986;24:207-15.[Medline]
  27. Kochiadakis GE, Kanoupakis EM, Kalebubas MD, Igoumenidis NE, Vardakis KE, Mavrakis HE, et al. Sotalol vs metoprolol for ventricular rate control in patients with chronic atrial fibrillation who have undergone digitalization: a single-blinded crossover study. Europace 2001;3:73-9.[Abstract/Free Full Text]
  28. Atwood JE, Myers J, Quaglietti S, Grumet J, Gianrossi R, Umman T. Effect of betaxolol on the hemodynamic, gas exchange, and cardiac output response to exercise in chronic atrial fibrillation. Chest 1999;115:1175-80.[CrossRef][ISI][Medline]
  29. Zoble RG, Brewington J, Olukotun AY, Gore R. Comparative effects of nadolol-digoxin combination therapy and digoxin monotherapy for chronic atrial fibrillation. Am J Cardiol 1987;60:39D-45D.[Medline]
  30. Maragno I, Santostasi G, Gaion RM, Trento M, Grion AM, Miraglia G, et al. Low- and medium-dose diltiazem in chronic atrial fibrillation: comparison with digoxin and correlation with drug plasma levels. Am Heart J 1988;116:385-92.[CrossRef][ISI][Medline]
  31. Botto GL, Bonini W, Broffoni T. Modulation of ventricular rate in permanent atrial fibrillation: randomized, crossover study of the effects of slow-release formulations of gallopamil, diltiazem, or verapamil. Clin Cardiol 1998;21:837-40.[ISI][Medline]
  32. Lewis RV, Laing E, Moreland TA, Service E, McDevitt DG. A comparison of digoxin, diltiazem and their combination in the treatment of atrial fibrillation. Eur Heart J 1988;9:279-83.[Abstract/Free Full Text]
  33. Roth A, Harrison E, Mitani G, Cohen J, Rahimtoola SH, Elkayam U. Efficacy and safety of medium- and high-dose diltiazem alone and in combination with digoxin for control of heart rate at rest and during exercise in patients with chronic atrial fibrillation. Circulation 1986;73:316-24.[ISI][Medline]
  34. Koh KK, Kwon KS, Park HB, Baik SH, Park SJ, Lee KH, et al. Efficacy and safety of digoxin alone and in combination with low-dose diltiazem or betaxolol to control ventricular rate in chronic atrial fibrillation. Am J Cardiol 1995;75:88-90.[CrossRef][ISI][Medline]
  35. Atwood JE, Myers JN, Sullivan MJ, Forbes SM, Pewen WF, Froelicher VF. Diltiazem and exercise performance in patients with chronic atrial fibrillation. Chest 1988;93:20-5.[CrossRef][ISI][Medline]
  36. Lundstrom T, Ryden L. Ventricular rate control and exercise performance in chronic atrial fibrillation: effects of diltiazem and verapamil. J Am Coll Cardiol 1990;16:86-90.[Abstract]
  37. Steinberg JS, Katz RJ, Bren GB, Buff LA, Varghese PJ. Efficacy of oral diltiazem to control ventricular response in chronic atrial fibrillation at rest and during exercise. J Am Coll Cardiol 1987;9:405-11.[Abstract]
  38. Theisen K, Haufe M, Peters J, Theisen F, Jahrmarker H. Effect of the calcium antagonist diltiazem on atrioventricular conduction in chronic atrial fibrillation. Am J Cardiol 1985;55:98-102.[CrossRef][ISI][Medline]
  39. Lewis R, Lakhani M, Moreland TA, McDevitt DG. A comparison of verapamil and digoxin in the treatment of atrial fibrillation. Eur Heart J 1987;8:148-53.[Abstract/Free Full Text]
  40. Pomfret SM, Beasley CR, Challenor V, Holgate ST. Relative efficacy of oral verapamil and digoxin alone and in combination for the treatment of patients with chronic atrial fibrillation. Clin Sci (Lond) 1988;74:351-7.[Medline]
  41. Lang R, Klein HO, Di Segni E, Gefen J, Sareli P, Libhaber C, et al. Verapamil improves exercise capacity in chronic atrial fibrillation: double-blind crossover study. Am Heart J 1983;105:820-5.[CrossRef][ISI][Medline]
  42. Lang R, Klein HO, Weiss E, David D, Sareli P, Levy A, et al. Superiority of oral verapamil therapy to digoxin in treatment of chronic atrial fibrillation. Chest 1983;83:491-9.[CrossRef][ISI][Medline]
  43. Stern EH, Pitchon R, King BD, Guerrero J, Schneider RR, Wiener I. Clinical use of oral verapamil in chronic and paroxysmal atrial fibrillation. Chest 1982;81:308-11.[CrossRef][ISI][Medline]
  44. Panidis IP, Morganroth J, Baessler C. Effectiveness and safety of oral verapamil to control exercise-induced tachycardia in patients with atrial fibrillation receiving digitalis. Am J Cardiol 1983;52:1197-201.[CrossRef][ISI][Medline]
  45. Schwartz JB, Keefe D, Kates RE, Kirsten E, Harrison DC. Acute and chronic pharmacodynamic interaction of verapamil and digoxin in atrial fibrillation. Circulation 1982;65:1163-70.[ISI][Medline]
  46. Klein HO, Pauzner H, Di Segni E, David D, Kaplinsky E. The beneficial effects of verapamil in chronic atrial fibrillation. Arch Intern Med 1979;139:747-9.[Abstract]
  47. Channer KS, Papouchado M, James MA, Pitcher DW, Rees JR. Towards improved control of atrial fibrillation. Eur Heart J 1987;8:141-7.[Abstract/Free Full Text]